REPATH LAUNCH
15 September 2026
Global
Genspect's REPATH campaign — calling for restored psychiatric assessment of gender dysphoria — launches on a day when several European health authorities are already quietly rewriting their own clinical guidelines. Stella O'Malley and Mia Hughes explain what re-psychopathologisation means in practice, and why the distinction between gender non-conformity and transgender ideation matters for every European clinician, regulator, and family navigating this landscape.
On today's episode, Stella O'Malley and Mia Hughes introduce REPATH — Genspect's Re-psychopathologisation Campaign — a formal call to restore psychiatric and psychological frameworks to the assessment of gender dysphoria. The campaign is precise about what it does and does not claim: gender non-conformity is not the target. What REPATH contests is the clinical norm that has taken hold in many countries, whereby a declaration of transgender identity moves a young person directly toward medical affirmation, bypassing the differential diagnosis, psychological evaluation, and co-morbidity screening that any other presentation of psychological distress would routinely receive. The European relevance is immediate. Sweden, Finland, Norway and Denmark have each issued national guidance in recent years restricting puberty blockers and cross-sex hormones for minors, citing insufficient evidence and the primacy of psychiatric care. In each case the underlying argument tracks closely with what REPATH now articulates as a campaign: that gender distress should be assessed and understood, not bypassed. What had been a series of cautious national clinical decisions now has a name, a coordinated framework, and an international organisation behind it. The timing also intersects with a tension at the institutional level. When the World Health Organisation reclassified gender incongruence in ICD-11, removing it from the mental disorders chapter, the practical message absorbed by many clinics and health systems was that psychiatric oversight was no longer expected. REPATH directly contests that reading. Restoring a psychiatric understanding, as O'Malley and Hughes explain, is not about stigma or pathologising identity; it is about ensuring that gender-distressed young people receive the same standard of investigative care that any other clinician would consider elementary due diligence. For European practitioners working under professional bodies that remain committed to affirmation-only guidance — in France, Germany, the Netherlands and elsewhere — this launch offers something concrete: a campaign with a clear position and the institutional backing of Genspect, whose work has become increasingly visible in post-Cass policy conversations across the continent. The language of differential diagnosis and re-psychopathologisation gives clinicians a framework they can cite within their own regulatory and collegial environments, without having to construct the argument from scratch. Parents and families across Europe are equally addressed. In countries where youth gender clinics remain open and affirmation-first, families seeking thorough psychiatric assessment for their children have often had to navigate that request without any clinical language to support it. REPATH supplies that language and signals that the demand for evaluation before medical intervention is not a fringe position but a growing international standard with professional advocates and an evidence base behind it. That a campaign of this scope is launching now reflects how rapidly the landscape has shifted since the Cass Review and the Scandinavian policy rollbacks. The outstanding question was whether the momentum those national decisions generated could be channelled into something durable and cross-border. What O'Malley and Hughes present today suggests it can. REPATH is less a conclusion than a starting point — a coordinated push to ensure that the question of why a young person is experiencing gender distress is asked, and answered, before any medical pathway is opened.
